Dyne BLA for z-rostudirsen under FDA Priority Review
Dyne Therapeutics reported Q3 financials and announced its z-rostudirsen BLA received FDA priority review with a PDUFA date of Jan 2027, marking a critical regulatory step for the treatment of Duchenne muscular dystrophy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed